Compare DCO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | NVCR |
|---|---|---|
| Founded | 1849 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1995 | 2015 |
| Metric | DCO | NVCR |
|---|---|---|
| Price | $163.08 | $14.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $153.60 | $28.08 |
| AVG Volume (30 Days) | 199.7K | ★ 1.6M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $824,730,000.00 | $655,353,000.00 |
| Revenue This Year | $7.40 | $7.72 |
| Revenue Next Year | $8.59 | $6.74 |
| P/E Ratio | $257.66 | ★ N/A |
| Revenue Growth | 4.85 | ★ 8.28 |
| 52 Week Low | $80.69 | $9.82 |
| 52 Week High | $168.74 | $18.92 |
| Indicator | DCO | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 38.70 |
| Support Level | $135.11 | $12.66 |
| Resistance Level | N/A | $18.59 |
| Average True Range (ATR) | 6.04 | 1.02 |
| MACD | 0.50 | -0.48 |
| Stochastic Oscillator | 75.38 | 16.53 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.